ASCO Annual Meeting | Conference

Atezolizumab Boosts Survival in Patients With NSCLC, Liver Mets

June 3rd 2019

Patients with non–small cell lung cancer and baseline liver metastases had improved progression-free survival and overall survival with the addition of immunotherapy to bevacizumab and a chemotherapy doublet.

New Targeted Therapies Show Promise for METex14-Altered NSCLC

June 3rd 2019

Two highly selective MET inhibitors, tepotinib and capmatinib showed promising clinical activity in the first- and second-line treatment of patients with MET exon 14-altered advanced non–small cell lung cancer.

Ramucirumab/Erlotinib Significantly Improves PFS in Frontline EGFR+ NSCLC

June 3rd 2019

Adding ramucirumab to erlotinib reduced the risk of disease progression or death by over 40% versus erlotinib alone as a frontline treatment for patients with EGFR-positive NSCLC.

FDA Streamlines Expanded Access for Oncology Agents

June 3rd 2019

The FDA has unveiled what it describes as a pilot “concierge service” for oncologists and patients seeking information and assistance with expanded access to investigational therapies.

Preoperative Immunotherapy Sends Positive Signals in 2 NSCLC Studies

June 3rd 2019

Neoadjuvant immunotherapy demonstrated substantial activity with a favorable toxicity profile in findings from 2 studies of patients with operable early-stage non–small cell lung cancer reported at the 2019 ASCO Annual Meeting.

Nearly Two-Thirds of Gynecologic Oncologists Report Being Sexually Harassed

June 3rd 2019

More than 70% of female gynecologic oncologists in the United States and more than half of male practitioners have experienced sexual harassment in training or practice, according to results from a survey conducted by the Society of Gynecologic Oncology.

Laparoscopic Surgery Found to Be Noninferior to Open Surgery Method for CRC Liver Metastases

June 3rd 2019

Similar long-term rates of survival were seen in patients with colorectal cancer and liver metastases regardless of whether the patient underwent laparoscopic or open liver surgery.

Broader Trial Criteria Would Almost Double Eligibility in Advanced NSCLC

June 3rd 2019

A broader set of clinical trial eligibility criteria proposed by the American Society of Clinical Oncology and Friends of Cancer Research would nearly double the number of patients with advanced non-small cell lung cancer available for enrollment.

Enfortumab Vedotin Produces Responses in Patients With Advanced Urothelial Carcinoma

June 3rd 2019

Enfortumab vedotin induced responses in 44% of patients with locally advanced or metastatic urothelial cancer, including 12% experiencing a complete response to treatment.

Dr. Golan on the Phase III POLO Trial in BRCA-Mutant Pancreatic Cancer

June 3rd 2019

Talia Golan, MD, head of Sheba Pancreatic Cancer Center, discusses the results of the phase III POLO trial, which evaluated maintenance olaparib compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer.

Dr. Sweeney on the Phase III ENZAMET Trial in Metastatic Hormone-Sensitive Prostate Cancer

June 3rd 2019

Christopher Sweeney, MBBS, medical oncologist at the Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, discusses results of the phase III ENZAMET trial, which looked at standard therapy with or without enzalutamide as a treatment for patients with metastatic hormone-sensitive prostate cancer.

Isatuximab Triplet Significantly Improves PFS in Myeloma

June 3rd 2019

Adding isatuximab to pomalidomide and low-dose dexamethasone led to a greater than 40% reduction in the risk of disease progression or death compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Subcutaneous Daratumumab Shows Similar Efficacy, Greater Convenience in Phase III Myeloma Trial

June 3rd 2019

A subcutaneous flat-dose version of daratumumab demonstrated noninferior efficacy with a reduction in the treatment burden compared with the original intravenous formulation of the anti-CD38 monoclonal antibody for patients with relapsed/refractory multiple myeloma.

High TMB Metastatic Breast Cancer Responds to Pembrolizumab Monotherapy

June 2nd 2019

Examination of a cohort of patients with metastatic breast cancer and high mutational burden who were enrolled in the phase II Targeted Agent and Profiling Utilization Registry basket study shows that pembrolizumab monotherapy has antitumor activity in this population of heavily pretreated patients.

Lurbinectedin Shows Promise as Single-Agent in Second-Line SCLC

June 2nd 2019

Lurbinectedin monotherapy achieved an overall response rate of 35.2% as a second-line treatment for patients with small cell lung cancer, according to findings from a phase II basket trial presented at the 2019 ASCO Annual Meeting.

Maintenance Olaparib Improves PFS in BRCA+ Metastatic Pancreatic Cancer

June 2nd 2019

Maintenance therapy with olaparib significantly improved progression-free survival compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer.

Enzalutamide Increases Survival in mHSPC Over Other Anti-Androgens

June 2nd 2019

Almost 80% of men with metastatic hormone-sensitive prostate cancer treated with enzalutamide plus standard of care (SOC) were alive after 3 years compared with 72% of patients who received a different non-steroidal anti-androgen plus SOC.

Alarm Sounded Over Multiple Myeloma Outcomes Versus Socioeconomics

June 2nd 2019

Higher income was associated with significantly greater probability of survival for patients with multiple myeloma, according to authors of a study they performed to call attention to the need to address socioeconomic disparities that influence treatment outcomes.

Medicaid Expansion Helps Reduce Racial Disparities in Access to Cancer Care

June 2nd 2019

The expansion of Medicaid nearly eliminated racial disparities in time to cancer treatment.

ACA Improved Ovarian Cancer Diagnosis and Time to Treatment

June 2nd 2019

Pre-Medicare-aged women with ovarian cancer were more likely to be diagnosed at an early stage and receive treatment within 30 days of diagnosis after passage of the Affordable Care Act than before.